Inflammation fueling atrial fibrillation substrate: Seeking ways to "cool" the heart

Medicinal Chemistry

Volumn 10, Issue 7, 2014, Pages 663-671

  Giannopoulos, Georgios ^a   Cleman, Michael W ^a   Deftereos, Spyridon ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti inflammatory; Atrial fibrillation; CRP; Inflammation; Interleukin

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COLCHICINE; CORTICOSTEROID; GELATINASE A; GELATINASE B; HIGH SENSITIVITY C REACTIVE PROTEIN; HYDROCORTISONE; INTERLEUKIN 6; INTERLEUKIN 8; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PREDNISOLONE; RESISTIN; SOLUBLE TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ABLATION THERAPY; ARTICLE; CARDIOVERSION; CLINICAL TRIAL (TOPIC); COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DNA POLYMORPHISM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE BIOPSY; HISTOLOGY; HUMAN; HYPERTENSION; INFLAMMATION; OBSERVATIONAL STUDY; PATHOGENESIS; PATHOPHYSIOLOGY; PERICARDITIS; PRIORITY JOURNAL; PULMONARY VEIN ISOLATION; RECURRENT DISEASE; SECONDARY PREVENTION; ATRIAL FIBRILLATION; COMPLICATION; METABOLISM;

ATRIAL FIBRILLATION; HUMANS; INFLAMMATION;

EID: 84925676542     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/1573406410666140318110100     Document Type: Article

References (90)

1. Go, A. S.; Hylek, E. M.; Phillips, K. A.; Chang, Y.; Henault, L. E.; Selby, J. V.; Singer, D. E. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA, 2001, 285, 2370-75.
2. Benjamin, E. J.; Wolf, P. A.; D'Agostino, R. B.; Silbershatz, H.; Kannel, W. B.; Levy, D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation, 1998, 98, 946-52.
3. Goto, S.; Bhatt, D. L.; Röther, J.; Alberts, M.; Hill, M. D.; Ikeda, Y.; Uchiyama, S.; D'Agostino, R.; Ohman, E. M.; Liau, C. S.; Hirsch, A. T.; Mas, J. L.; Wilson, P. W.; Corbalán, R.; Aichner, F.; Steg, P. G.; REACH Registry Investigators, Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am. Heart J., 2008, 156, 855-63.
4. Mamas, M. A.; Caldwell, J. C.; Chacko, S.; Garratt, C. J.; Fath-Ordoubadi, F.; Neyses, L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur. J. Heart Fail. 2009, 11, 676-83.
5. Hart, R. G.; Pearce, L. A. Current status of stroke risk stratification in patients with atrial fibrillation. Stroke, 2009, 40, 2607-10.
6. Jørgensen, H. S.; Nakayama, H.; Reith, J.; Raaschou, H. O.; Olsen, T. S. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke, 1996, 27, 1765-9.
7. Chung, M. K.; Martin, D. O.; Sprecher, D.; Wazni, O.; Kanderian, A.; Carnes, C. A.; Bauer, J. A.; Tchou, P. J.; Niebauer, M. J.; Natale, A.; Van Wagoner, D. R. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation, 2001, 104, 2886-91.
8. Devaraj, S.; Singh, U.; Jialal, I. The evolving role of C-reactive protein in atherothrombosis. Clin. Chem., 2009, 55, 229-38.
9. Aviles, R. J.; Martin, D. O.; AppersoN-Hansen, C.; Houghtaling, P. L.; Rautaharju, P.; Kronmal, R. A.; Tracy, R. P.; Van Wagoner, D. R.; Psaty, B. M.; Lauer, M. S.; Chung, M. K. Inflammation as a risk factor for atrial fibrillation. Circulation, 2003, 108, 3006-10.
10. Peña, J. M.; MacFadyen, J.; Glynn, R. J.; Ridker, P. M. Highsensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur. Heart J., 2012, 33, 531-7.
11. Liu, T.; Li, G.; Li, L.; Korantzopoulos, P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J. Am. Coll. Cardiol., 2007, 49, 1642-8.
12. Wazni, O.; Martin, D. O.; Marrouche, N. F.; Shaaraoui, M.; Chung, M. K.; Almahameed, S.; Schweikert, R. A.; Saliba, W. I.; Natale, A. C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart, 2005, 91, 1303-5.
13. Malouf, J. F.; Kanagala, R.; Al Atawi, F. O.; Rosales, A. G.; Davison, D. E.; Murali, N. S.; Tsang, T. S.; Chandrasekaran, K.; Ammash, N. M.; Friedman, P. A.; Somers, V. K. High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion. J. Am. Coll. Cardiol., 2005, 46, 1284-7.
14. Watanabe, E.; Arakawa, T.; Uchiyama, T.; Kodama, I.; Hishida, H. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int. J. Cardiol., 2006, 108, 346-53.
15. Zarauza, J.; Rodríguez Lera, M. J.; Fariñas Alvarez, C.; Hernando, J. P.; Ceballos, B.; Gutiérrez, B.; Pérez, J.; Cuesta, J. M. Relationship between C-reactive protein level and early recurrence of atrial fibrillation after electrical cardioversion. Rev. Esp. Cardiol., 2006, 59, 125-9.
16. Korantzopoulos, P.; Kolettis, T. M.; Kountouris, E.; Siogas, K.; Goudevenos, J. A. Variation of inflammatory indexes after electrical cardioversion of persistent atrial fibrillation. Is there an association with early recurrence rates? Int. J. Clin. Pract., 2005, 59, 881-5.
17. Cosgrave, J.; Foley, J. B.; Bahadur, K.; Bennett, K.; Crean, P.; Walsh, M. J. Inflammatory markers are not associated with outcomes following elective external cardioversion. Int. J. Cardiol., 2006, 110, 373-7.
18. Buob, A.; Jung, J.; Siaplaouras, S.; Neuberger, H. R.; Mewis, C. Discordant regulation of CRP and NT-proBNP plasma levels after electrical cardioversion of persistent atrial fibrillation. Pacing Clin. Electrophysiol., 2006, 29, 559-63.
19. Kawamura, M.; Munetsugu, Y.; Kawasaki, S.; Onishi, K.; Onuma, Y.; Kikuchi, M.; Tanno, K.; Kobayashi, Y. Type III procollageN-N-peptide as a predictor of persistent atrial fibrillation recurrence after cardioversion. Europace, 2012, 14, 1719-25.
20. Marcus, G. M.; Smith, L. M.; Ordovas, K.; Scheinman, M. M.; Kim, A. M.; Badhwar, N.; Lee, R. J.; Tseng, Z. H.; Lee, B. K.; Olgin, J. E. Intracardiac and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm, 2010, 7, 149-54.
21. Masson, S.; Aleksova, A.; Favero, C.; Staszewsky, L.; Bernardinangeli, M.; Belvito, C.; Cioffi, G.; Sinagra, G.; Mazzone, C.; Bertocchi, F.; Vago, T.; Peri, G.; Cuccovillo, I.; Masuda, N.; Barlera, S.; Mantovani, A.; Maggioni, A. P.; Franzosi, M. G.; Disertori, M.; Latini, R.; GISSI-AF investigators, Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trial. Heart, 2010, 96, 1909-14.
22. Deftereos, S.; Giannopoulos, G.; Kossyvakis, C.; Raisakis, K.; Angelidis, C.; Efremidis, M.; Panagopoulou, V.; Kaoukis, A.; Theodorakis, A.; Toli, K.; Zavitsanakis, P.; Mantas, I.; Pyrgakis, V.; Stefanadis, C.; Cleman, M. W. Association of post-cardioversion transcardiac concentration gradient of soluble tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL) and inflammatory biomarkers to atrial fibrillation recurrence. Clin. Biochem., 2013, 46, 1020-5.
23. Ellinor, P. T.; Low, A.; Patton, K. K.; Shea, M. A.; MacRae, C. A. C-Reactive protein in lone atrial fibrillation. Am. J. Cardiol., 2006, 97, 1346-50.
24. Yao, S. Y.; Chu, J. M.; Chen, K. P.; Tang, M.; Fang, P. H.; Wang, F. Z.; Zhang, S. Inflammation in lone atrial fibrillation. Clin. Cardiol., 2009, 32, 94-8.
25. Conway, D. S.; Buggins, P.; Hughes, E.; Lip, G. Y. Relationship of interleukiN-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J. Am. Coll. Cardiol., 2004, 43, 2075-82.
26. Marott, S. C.; Nordestgaard, B. G.; Zacho, J.; Friberg, J.; Jensen, G. B.; Tybjaerg-Hansen, A.; Benn, M. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47, 000 individuals from the general population. J. Am. Coll. Cardiol., 2010, 56, 789-95.
27. Psychari, S. N.; Apostolou, T. S.; Sinos, L.; Hamodraka, E.; Liakos, G.; Kremastinos, D. T. Relation of elevated C-reactive protein and interleukiN-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am. J. Cardiol., 2005, 95, 764-7.
28. Burzotta, F.; Iacoviello, L.; Di Castelnuovo, A.; Glieca, F.; Luciani, N.; Zamparelli, R.; Schiavello, R.; Donati, M. B.; Maseri, A.; Possati, G.; Andreotti, F. Relation of the -174 G/C polymorphism of interleukiN-6 to interleukiN-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am. J. Cardiol., 2001, 88, 1125-8.
29. Marcus, G. M.; Whooley, M. A.; Glidden, D. V.; Pawlikowska, L.; Zaroff, J. G.; Olgin, J. E. InterleukiN-6 and atrial fibrillation in patients with coronary artery disease: Data from the Heart and Soul Study. Am. Heart. J., 2008, 155, 303-9.
30. Deftereos, S.; Giannopoulos, G.; Kossyvakis, C.; Efremidis, M.; Panagopoulou, V.; Kaoukis, A.; Raisakis, K.; Bouras, G.; Angelidis, C.; Theodorakis, A.; Driva, M.; Doudoumis, K.; Pyrgakis, V.; Stefanadis, C. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J. Am. Coll. Cardiol., 2012, 60, 1790-6.
31. De Gennaro, L.; Brunetti, N. D.; Montrone, D.; De Rosa, F.; Cuculo, A.; Di Biase, M. Inflammatory activation and carbohydrate antigeN-125 levels in subjects with atrial fibrillation. Eur. J. Clin. Invest., 2012, 42, 371-5.
32. Liuba, I.; Ahlmroth, H.; Jonasson, L.; Englund, A.; Jönsson, A.; Säfström, K.; Walfridsson, H. Source of inflammatory markers in patients with atrial fibrillation. Europace, 2008, 10, 848-53.
33. Scridon, A.; Morel, E.; NoniN-Babary, E.; Girerd, N.; Fernandez, C.; Chevalier, P. Increased intracardiac vascular endothelial growth factor levels in patients with paroxysmal, but not persistent atrial fibrillation. Europace, 2012, 14, 948-53.
34. Gungor, B.; Ekmekci, A.; Arman, A.; Ozcan, K. S.; Ucer, E.; Alper, A. T.; Calik, N.; Yilmaz, H.; Tezel, T.; Coker, A.; Bolca, O. Assessment of interleukiN-1 gene cluster polymorphisms in lone atrial fibrillation: new insight into the role of inflammation in atrial fibrillation. Pacing Clin. Electrophysiol., 2013, 36, 1220-7.
35. Neuman, R. B.; Bloom, H. L.; Shukrullah, I.; Darrow, L. A.; Kleinbaum, D.; Jones, D. P.; Dudley, S. C. Jr. Oxidative stress markers are associated with persistent atrial fibrillation. Clin. Chem., 2007, 53, 1652-7.
36. Meldrum, D. R. Tumor necrosis factor in the heart. Am. J. Physiol., 1998, 274, R577-95.
37. Cain, B. S.; Meldrum, D. R.; Dinarello, C. A.; Meng, X.; Joo, K. S.; Banerjee, A.; Harken, A. H. Tumor necrosis factor-alpha and interleukiN-1beta synergistically depress human myocardial function. Crit. Care Med., 1999, 27, 1309-18.
38. Bryant, D.; Becker, L.; Richardson, J.; Shelton, J.; Franco, F.; Peshock, R.; Thompson, M.; Giroir, B. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation, 1998, 97, 1375-81.
39. Liew, R.; Khairunnisa, K.; Gu, Y.; Tee, N.; Yin, N. O.; Naylynn, T. M.; Moe, K. T. Role of tumor necrosis factor-a in the pathogenesis of atrial fibrosis and development of an arrhythmogenic substrate. Circ. J., 2013, 77, 1171-9.
40. Lee, S. H.; Chen, Y. C.; Chen, Y. J.; Chang, S. L.; Tai, C. T.; Wongcharoen, W.; Yeh, H. I.; Lin, C. I.; Chen, S. A. Tumor necrosis factor-alpha alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes. Life Sci., 2007, 80, 1806-15.
41. Qu, Y. C.; Du, Y. M.; Wu, S. L.; Chen, Q. X.; Wu, H. L.; Zhou, S. F. Activated nuclear factor-kappa and increased tumor necrosis factoralpha in atrial tissue of atrial fibrillation. Scand. Cardiovasc. J., 2009, 43, 292-7.
42. Li, J.; Solus, J.; Chen, Q.; Rho, Y. H.; Milne, G.; Stein, CM.; Darbar, D. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm, 2010, 7, 438-44.
43. Schnabel, R. B.; Larson, M. G.; Yamamoto, J. F.; Kathiresan, S.; Rong, J.; Levy, D.; Keaney, J. F. Jr.; Wang, T. J.; Vasan, R. S.; Benjamin, E. J. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am. J. Cardiol, 2009, 104, 92-6.
44. Müller-Quernheim, J. MMPs are regulatory enzymes in pathways of inflammatory disorders, tissue injury, malignancies and remodelling of the lung. Eur. Respir. J., 2011, 38, 12-4.
45. Nakano, Y.; Niida, S.; Dote, K.; Takenaka, S.; Hirao, H.; Miura, F.; Ishida, M.; Shingu, T.; Sueda, T.; Yoshizumi, M.; Chayama, K. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J. Am. Coll. Cardiol, 2004, 43, 818-25.
46. Mukherjee, R.; Akar, J. G.; Wharton, J. M.; Adams, D. K.; McClure, CD.; Stroud, R. E.; Rice, A. D.; De Santis, S. M.; Spinale, F. G.; Gold, M. R. Plasma profiles of matrix metalloproteinases and tissue inhibitors of the metalloproteinases predict recurrence of atrial fibrillation following cardioversion. J. Cardiovasc. Transl. Res., 2013, 6, 528-35.
47. Wang, X.; Li, Y.; Liu, L.; Hu, S. S.; Song, Y. H.; Wang, W. The role of matrix metalloproteinase-2 in the treatment of atrial fibrillation recurrence after a radiofrequency modified maze procedure. Cardiology, 2013, 126, 62-8.
48. Xu, J.; Cui, G.; Esmailian, F.; Plunkett, M.; Marelli, D.; Ardehali, A.; Odim, J.; Laks, H.; Sen, L. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation, 2004, 109, 363-8.
49. Huxley, R. R.; Lopez, F. L.; MacLehose, R. F.; Eckfeldt, J. H.; Couper, D.; Leiendecker-Foster, C; Hoogeveen, R. C; Chen, L. Y.; Soliman, E. Z.; Agarwal, S. K.; Alonso, A. Novel association between plasma matrix metalloproteinase-9 and risk of incident atrial fibrillation in a case-cohort study: the Atherosclerosis Risk in Communities study. PLoS One, 2013, 8, e59052.
50. Kalogeropoulos, A. S.; Tsiodras, S.; Rigopoulos, A. G.; Sakadakis, E. A.; Triantafyllis, A.; Kremastinos, D. T.; Rizos, I. Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation. BMC Cardiovasc. Disord., 2011, 1, 77.
51. Lombardi, F.; Belletti, S.; Battezzati, P. M.; Pacciolla, R.; Biondi, M. L. MMP-1 and MMP-3 polymorphism and arrhythmia recurrence after electrical cardioversion in patients with persistent atrial fibrillation. J. Cardiovasc. Med. (Hagerstown), 2011, 12, 37-42.
52. Kaireviciute, D.; Blann, A. D.; Balakrishnan, B.; Lane, D. A.; Patel, J. V.; Uzdavinys, G.; Norkunas, G.; Kalinauskas, G.; Sirvydis, V.; Aidietis, A.; Lip, G. Y. Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. Thromb. Haemost., 2010, 104, 122-7.
53. Kaireviciute, D.; Lip, G. Y.; Balakrishnan, B.; Uzdavinys, G.; Norkunas, G.; Kalinauskas, G.; Sirvydis, V.; Aidietis, A.; Zanetto, U.; Sihota, H.; Maheshwari, M.; Blann, A. D. Intracardiac expression of markers of endothelial damage/dysfunction, inflammation, thrombosis, and tissue remodeling, and the development of postoperative atrial fibrillation. J. Thromb. Haemost., 2011, 9, 2345-52.
54. Ozcan, K. S.; Güngör, B.; Altay, S.; Osmonov, D.; Ekmekçi, A.; Ozpamuk, F.; Kemaloglu, T.; Yildirim, A.; Tayyareci, G.; Erdinler, I. Increased level of resistin predicts development of atrial fibrillation. J. Cardiol, 2013, doi: 10.1016/j.jjcc.2013.10.008.
55. Rienstra, M.; Sun, J. X.; Lubitz, S. A.; Frankel, D. S.; Vasan, R. S.; Levy, D.; Magnani, J. W.; Sullivan, L. M.; Meigs, J. B.; Ellinor, P. T.; Benjamin, E. J. Plasma resistin, adiponectin, and risk of incident atrial fibrillation: the Framingham Offspring Study. Am. Heart J., 2012, 163, 119-24.
56. Gibson, P. H.; Cuthbertson, B. H.; Croal, B. L.; Rae, D.; El-Shafei, H.; Gibson, G.; Jeffrey, R. R.; Buchan, K. G.; Hillis, G. S. Usefulness of neutrophil/lymphocyte ratio as predictor of new-onset atrial fibrillation after coronary artery bypass grafting. Am. J. Cardiol, 2010, 105, 186-91.
57. Canpolat, U.; Aytemir, K.; Yorgun, H.; Sahiner, L.; Kaya, E. B.; Kabakçi, G.; Tokgözoglu, L.; Oto, A. Role of preablation neutrophil/lymphocyte ratio on outcomes of cryoballooN-based atrial fibrillation ablation. Am. J. Cardiol, 2013, 112, 513-9.
58. Güngör, B.; Ozcan, K. S.; Erdinler, I.; Ekmekçi, A.; Alper, A. T.; Osmonov, D.; Calik, N.; Akyuz, S.; Toprak, E.; Yilmaz, H.; Yildirim, A.; Bolca, O. Elevated levels of RDW is associated with noN-valvular atrial fibrillation. J. Thromb. Thrombolysis, 2013, doi:10.1007/s1 1239-013-0957-1.
59. Fontes, M. L.; Mathew, J. P.; Rinder, H. M.; Zelterman, D.; Smith, B. R.; Rinder, C. S.; Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Atrial fibrillation after cardiac surgery/cardiopulmonary bypass is associated with monocyte activation. Anesth. Analg., 2005, 101, 17-23.
60. Yamashita, T.; Sekiguchi, A.; Iwasaki, Y. K.; Date, T.; Sagara, K.; Tanabe, H.; Suma, H.; Sawada, H.; Aizawa, T. Recruitment of immune cells across atrial endocardium in human atrial fibrillation. Circ. J., 2010, 74, 262-70.
61. Castonguay, M. C; Wang, Y.; Gerhart, J. L.; Miller, D. V.; Stulak, J. M.; Edwards, W. D.; Maleszewski, J. J. Surgical pathology of atrial appendages removed during the cox-maze procedure: a review of 86 cases (2004 to 2005) with implications for prognosis. Am. J. Surg. Pathol, 2013, 37, 890-7.
62. Albert, M. A.; Danielson, E.; Rifai, N.; Ridker, P. M.; for the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels. JAMA, 2001, 286, 64-70.
63. Patti, G.; Chello, M.; Candura, D.; Pasceri, V.; D'Ambrosio, A.; Covino, E.; Di Sciascio, G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation, 2006, 114, 1455-61.
64. Maggioni, A. P.; Fabbri, G.; Lucci, D.; Marchioli, R.; Franzosi, M. G.; Latini, R.; Nicolosi, G. L.; Porcu, M.; Cosmi, F.; Stefanelli, S.; Tognoni, G.; Tavazzi, L.; on behalf of the GISSI-HF Investigators. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J, 2009, 30, 2327-36.
65. Schwartz, G. G.; Chaitman, B. R.; Goldberger, J. J.; Messig, M. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Am. Heart J., 2011, 161, 993-9.
66. Rahimi, K.; Emberson, J.; McGale, P.; Majoni, W.; Merhi, A.; Asselbergs, F. W.; Krane, V.; Macfarlane, P. W.; PROSPER Executive. Effect of statins on atrial fibrillation: collaborative metaanalysis of published and unpublished evidence from randomised controlled trials. BMJ, 2011, 342, d1250.
67. Almroth, H.; Höglund, N.; Boman, K.; Englund, A.; Jensen, S.; Kjellman, B.; Tornvall, P.; Rosenqvist, M. Atorvastatin and persistent atrial fibrillation after cardioversion: a randomized placebo controlled multicentre study. Eur. Heart J., 2009, 30, 827-33.
68. Suleiman, M.; Koestler, C; Lerman, A.; Lopez-Jimenez, F.; Herges, R.; Hodge, D.; Bradley, D.; Cha, Y. M.; Brady, P. A.; Munger, T. M.; Asirvatham, S. J.; Packer, D. L.; Friedman, P. A. Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: a double-blind, placebo-controlled, randomized trial. Heart Rhythm, 2012, 9, 172-8.
69. Deftereos, S.; Giannopoulos, G.; Papoutsidakis, N.; Panagopoulou, V.; Kossyvakis, C; Raisakis, K.; Cleman, M. W.; Stefanadis, C. Colchicine and the heart: pushing the envelope. J. Am. Coll. Cardiol, 2013, 62, 1817-25.
70. Imazio, M.; Brucato, A.; Ferrazzi, P.; Rovere, M. E.; Gandino, A.; Cemin, R.; Ferrua, S.; Belli, R.; Maestroni, S.; Simon, C; Zingarelli, E.; Barosi, A.; Sansone, F.; Patrini, D.; Vitali, E.; Trinchero, R.; Spodick, D. H.; Adler, Y.; COPPS Investigators. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation, 2011, 124, 2290-5.
71. Koyama, T.; Sekiguchi, Y.; Tada, H.; Arimoto, T.; Yamasaki, H.; Kuroki, K.; Machino, T.; Tajiri, K.; Zhu, X. D.; Kanemoto M.; Sugiyasu A.; Kuga K.; Aonuma K. Comparison of characteristics and significance of immediate versus early versus no recurrence of atrial fibrillation after catheter ablation. Am. J. Cardiol, 2009, 103, 1249-54.
72. McCabe, J. M.; Smith, L. M.; Tseng, Z. H.; Badhwar, N.; Lee, B. K.; Lee, R. J.; Scheinman, M. M.; Olgin, J. E.; Marcus, G. M. Protracted CRP elevation after atrial fibrillation ablation. Pacing Clin. Electrophysiol, 2008, 31, 1146-51.
73. Koyama, T.; Tada, H.; Sekiguchi, Y.; Arimoto, T.; Yamasaki, H.; Kuroki, K.; Machino, T.; Tajiri, K.; Zhu, X. D.; Kanemoto-Igarashi, M.; Sugiyasu, A.; Kuga, K.; Nakata, Y.; Aonuma, K. Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation: a randomized controlled trial. J. Am. Coll. Cardiol, 2010, 56, 1463-72.
74. Shiroshita-Takeshita, A.; Brundel, B J.; Lavoie, J.; Nattel, S. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc. Res., 2006, 69, 865.
75. Goldstein, R. N.; Ryu, K.; Khrestian, C; Van Wagoner, D. R.; Waldo, A. L. Prednisone prevents inducible atrial flutter in the canine sterile pericarditis model. J. Cardiovasc. Electrophysiol, 2008, 19, 74-81.
76. Marik, P. E.; Fromm, R. The efficacy and dosage effect of corticosteroids for the prevention of atrial fibrillation after cardiac surgery: A systematic review. J. Crit. Care, 2009, 24, 458-3.
77. Halvorsen, P.; Raeder, J.; White, P. F.; Almdahl, S. M.; Nordstrand, K.; Saatvedt, K.; Veel, T. The effect of dexamethasone on side effects after coronary revascularization procedures. Anesth. Analg., 2003, 96, 1578-83.
78. Halonen, J.; Halonen, P.; Järvinen, O.; Taskinen, P.; Auvinen, T.; Tarkka, M.; Hippelainen, M.; Juvonen, T.; Hartikainen, J.; Hakala, T. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: A randomized controlled trial. JAMA, 2007, 297, 1562-67.
79. Ho, K. M.; Tan, J. A. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: A dose-response meta-analysis. Circulation, 2009, 119, 1853-66.
80. Prasongsukarn, K.; Abel, J. G.; Jamieson, W. R.; Cheung, A.; Russell, J. A.; Walley, K. R.; Lichtenstein, S. V. The effects of steroids on the occurrence of postoperative atrial fibrillation after coronary artery bypass grafting surgery: A prospective randomized trial. J. Thorac. Cardiovasc. Surg., 2005, 130, 93-8.
81. Rodrigo, R.; Korantzopoulos, P.; Cereceda, M.; Asenjo, R.; Zamorano, J.; Villalabeitia, E.; Baeza, C; Aguayo, R.; Castillo, R.; Carrasco, R.; Gormaz, J. G. A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement. J. Am. Coll. Cardiol, 2013, 62, 1457-65.
82. Calò, L.; Bianconi, L.; Colivicchi, F.; Lamberti, F.; Loricchio, M. L.; De Ruvo, E.; Meo, A.; Pandozi, C; Staibano, M.; Santini, M. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J. Am. Coll. Cardiol, 2005, 45, 1723-8.
83. Mayyas, F.; Sakurai, S.; Ram, R.; Rennison, J. H.; Hwang, E. S.; Castel, L.; Lovano, B.; Brennan, M. L.; Bibus, D.; Lands, B.; Barnard, J.; Chung, M. K.; Van Wagoner, D. R. Dietary co3 fatty acids modulate the substrate for post-operative atrial fibrillation in a canine cardiac surgery model. Cardiovasc. Res., 2011, 89, 852-61.
84. Zhang, Z.; Zhang, C; Wang, H.; Zhao, J.; Liu, L.; Lee, J.; He, Y.; Zheng, Q. N-3 polyunsaturated fatty acids prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Int. J. Cardiol, 2011, 153, 14-20.
85. Wu, J. H.; Marchioli, R.; Silletta, M. G.; Macchia, A.; Song, X.; Siscovick, D. S.; Harris, W. S.; Masson, S.; Latini, R.; Albert, C; Brown, N. J.; Lamarra, M.; Favaloro, R. R.; Mozaffarian, D. Plasma phospholipid omega-3 fatty acids and incidence of postoperative atrial fibrillation in the OPERA trial. J. Am. Heart Assoc, 2013, 2, e000397.
86. Rix, T. A.; Joensen, A. M.; Riahi, S.; Lundbye-Christensen, S.; Overvad, K.; Schmidt, E. B. Marine N-3 fatty acids in adipose tissue and development of atrial fibrillation: a Danish cohort study. Heart, 2013, 99, 1519-24.
87. Aleksova, A.; Masson, S.; Maggioni, A. P.; Lucci, D.; Fabbri, G.; Beretta, L.; Mos, L.; Paino, A. M.; Nicolosi, G. L.; Marchioli, R.; Tognoni, G.; Tavazzi, L.; Sinagra, G.; Latini, R.; GISSI-Heart Failure Investigators. N-3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI-HF trial. Eur. J. Heart Fail, 2013, 15, 1289-95.
88. Kumar, S.; Sutherland, F.; Morton, J. B.; Lee, G.; Morgan, J.; Wong, J.; Eccleston, D. E.; Voukelatos, J.; Garg, M. L.; Sparks, P. B. Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion. Heart Rhythm, 2012, 9, 483-91.
89. Bianconi, L.; Calò, L.; Mennuni, M.; Santini, L.; Morosetti, P.; Azzolini, P.; Barbato, G.; Biscione, F.; Romano, P.; Santini, M. N-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study. Europace, 2011, 13, 174-81.
90. Macchia, A.; Grancelli, H.; Varini, S.; Nul, D.; Laffaye, N.; Mariani, J.; Ferrante, D.; Badra, R.; Figal, J.; Ramos, S.; Tognoni, G.; Doval, H. C.; GESICA Investigators. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial. J. Am. Coll. Cardiol., 2013, 61, 463-8.